Safety and efficacy of cefpirome among Filipino patients.
- Author:
Benedicto Jubert P.
- Publication Type:Clinical trials/Clinical investigations (RCT's)
- MeSH: Human; Male; Female; Aged; Middle Aged; Adult; Cefpirome; Anti-bacterial Agents; Anti-infective Agents; Cephalosporins; Communicable Diseases; Pneumonia; Morbidity
- From: Philippine Journal of Internal Medicine 2015;53(4):1-5
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND: Infectious diseases remain a significant cause of morbidity and mortality. Cefpirome, a fourth generation Cephalosporin, is a potent antibiotic against a wide variety of organisms that may be used alone or in combination with other antimicrobials to combat various infections.
OBJECTIVE: This is a post-marketing surveillance study documenting the safety and efficacy of cefpirome among Filipino patients.
METHODOLOGY: This was a multicenter, open-label, noncomparative study involving 402 patients who received at least one dose of cefpirome. Safety and efficacy data were gathered.
RESULTS: Cefpirome was used as monotherapy in majority of the cases. Pneumonia (76%) was the most frequent indication for the use of this drug. The most commonly utilized dosage regimen was 2.0 grams every 12 hours for a mean of 4.2 days. This was associated with a successful clinical outcome in almost 90% of cases. There was almost negligible side effect reported.
CONCLUSION: The use of cefpirome was shown to be safe and well-tolerated with associated successful clinical outcomes among Filipino patients.